As rates of syphilis and HIV continue to climb in Canada, a dual rapid test recently was approved by federal regulators,.

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical ...

Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials ...

The approval of the ITA is an important step towards getting the Multiplo® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Medmira ( (TSE ...

Amid these soaring cases, particularly in underserved and remote communities in the Prairies, the Multiplo® TP/HIV rapid self-test and non-professional tests provides a 'missing key' to help reach the ...